|
This international, randomized, phase III trial will determine if the addition of whole brain radiotherapy after surgery or local stereotactic radiotherapy improves the control of melanoma metastases in the brain, neurocognitive function, survival and quality of life.
Click here for more information
Neurotropism, defined as invasion by melanoma of peripheral neural tissue, is uncommon but it is this feature which is linked with a high risk of the cancer coming back in the same area. The primary aim of this trial is to determine if there is a difference in the rate of relapse between 2 randomised groups of patients treated after surgery with either radiation therapy or initial observation. Click here for more information
There is currently no high evidence to show that Vitamin D can improve melanoma prognosis. This is a pilot phase II study which aims to determine whether administration of a loading oral dose of 500,000 IU of Vitamin D followed by a monthly oral dose of 50,000 IU of Vitamin D for 2 years following primary treatment of melanoma at high risk of recurrence. Click here for more information
Oral kinase inhibitors are proving to be effective in up to 60% of malignant melanomas that are found to have a BRAF mutation. However, drug resistance is emerging and many patients relapse affirming the need for further treatment development. This Phase I study is assessing the safety and immune effects of using autologous peripheral blood T cells in GD2 positive patients being treated with vemurafenib. Click here for more information
EOTR QoL Module Click here for more information
A phase III multicenter randomised trial of sentinel lymphadenectomy and complete lymph node dissection versus sentinel lyphadenectomy alone, in cutaneous melanoma patients with molecular or histopathological evidence of metastases in the sentinel node (MSLT II).
Click here for more information
Spread of metastatic melanoma to the groin lymph nodes is a common event for patients with melanoma. In melanoma treatment centres around the world, management of patients with clear pelvic lymph node disease vary. Thismulti-centre, phase III, prospective, randomised clinical trial aims to assess the effectiveness and morbidity of Complete Inguinal Lymphadenectomy versus Complete Ilio-ingional Lymphadenectomy for patients with metastatic melanoma and negative pelvic staging on PET / CT scan.
Click here for more information
To date, there have been no prospective studies or randomised controlled trials (RCT) conducted to form the basis of any recommendations for the management of Lentigo Maligna. In order to establish the optimum management for these patients and to accurately evaluatethese treatments a prospective randomised controlled clinical trial is required.
Click here for more information
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with a primary invasive cutaneous melanomas >=1mm thick to determine differences in the rate of local recurrence and melanoma specific survival. A reduction in margins is expected to improve quality of life in patients. Click here for more information
There are very few psychosocial resources designed to address the information and support needs of melanoma patients. This randomised controlled clinical trials aims to evaluate the efficacy of a psycho-educational intervention in reducing fear of melanoma recurrence (defined in this study as fear of melanoma recurrence as well as fear of developing new primary disease) in melanoma survivors at high risk of developing new primary melanoma, compared to usual care.
Click here for more information
A phase II study of nivolumab and nivolumab in combination with ipilimumab in patients with melanoma brain metastases. Click here for more information
An open-label, single-arm, phase I/II, multicenter study to evaluate the safety and efficacy of the combination of dabrafenib, trametinib and palliative radiotherapy in patients with inoperable (stage IIIc) and metastatic (stage IV) BRAF V600E/K mutation-positive cutaneous melanoma.
Click here for more information
|